# A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

Source: https://onco.cc/trials/nct05548296/  
OnCo record `nct05548296` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Gemcitabine in endometrial cancer, run by Acrivon Therapeutics, now recruiting.

## Summary

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma is a phase 2 interventional study registered as NCT05548296 by Acrivon Therapeutics, with 350 participants planned, started 2022-08-29 and due to reach its primary completion in 2027-05-30. Interventions recorded: ACR-368 and Gemcitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05548296
- Phase: 2
- Setting: A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer
- Sponsor: Acrivon Therapeutics
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT05548296: https://clinicaltrials.gov/study/NCT05548296

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- companies: [Acrivon Therapeutics](https://onco.cc/companies/acrivon-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05548296.json